iTeos Therapeutics, Inc.
ITOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $311 | $392 | $694 | $1,638 |
| - Cash | $142 | $251 | $285 | $849 |
| + Debt | $5 | $6 | $5 | $5 |
| Enterprise Value | $174 | $146 | $414 | $795 |
| Revenue | $35 | $13 | $268 | $345 |
| % Growth | 177.9% | -95.3% | -22.4% | – |
| Gross Profit | $34 | $12 | $267 | $344 |
| % Margin | 96.5% | 92.9% | 99.7% | 99.8% |
| EBITDA | -$122 | -$112 | $148 | $257 |
| % Margin | -348.1% | -886.5% | 55.4% | 74.6% |
| Net Income | -$134 | -$113 | $97 | $215 |
| % Margin | -384% | -894.3% | 36.1% | 62.2% |
| EPS Diluted | -3.32 | -3.15 | 2.56 | 5.68 |
| % Growth | -5.4% | -223% | -54.9% | – |
| Operating Cash Flow | -$98 | -$104 | -$111 | $513 |
| Capital Expenditures | -$2 | -$3 | -$1 | -$1 |
| Free Cash Flow | -$100 | -$107 | -$112 | $512 |